Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Tirzepatide is a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist that is under development for the treatment of type 2 diabetes. The efficacy and safety of once-weekly tirzepatide as compared with semaglutide, a selective GLP-1 receptor agonist, are unknown. METHODS: In an open-label, 40-week, phase 3 trial, we randomly assigned 1879 patients, in a 1:1:1:1 ratio, to receive tirzepatide at a dose of 5 mg, 10 mg, or 15 mg or semaglutide at a dose of 1 mg. At baseline, the mean glycated hemoglobin level was 8.28%, the mean age 56.6 years, and the mean weight 93.7 kg. The primary end point was the change in the glycated hemoglobin level from baseline to 40 weeks. RESULTS: The estimated mean change from baseline in the glycated hemoglobin level was -2.01 percentage points, -2.24 percentage points, and -2.30 percentage points with 5 mg, 10 mg, and 15 mg of tirzepatide, respectively, and -1.86 percentage points with semaglutide; the estimated differences between the 5-mg, 10-mg, and 15-mg tirzepatide groups and the semaglutide group were -0.15 percentage points (95% confidence interval [CI], -0.28 to -0.03; P = 0.02), -0.39 percentage points (95% CI, -0.51 to -0.26; P<0.001), and -0.45 percentage points (95% CI, -0.57 to -0.32; P<0.001), respectively. Tirzepatide at all doses was noninferior and superior to semaglutide. Reductions in body weight were greater with tirzepatide than with semaglutide (least-squares mean estimated treatment difference, -1.9 kg, -3.6 kg, and -5.5 kg, respectively; P<0.001 for all comparisons). The most common adverse events were gastrointestinal and were primarily mild to moderate in severity in the tirzepatide and semaglutide groups (nausea, 17 to 22% and 18%; diarrhea, 13 to 16% and 12%; and vomiting, 6 to 10% and 8%, respectively). Of the patients who received tirzepatide, hypoglycemia (blood glucose level, <54 mg per deciliter) was reported in 0.6% (5-mg group), 0.2% (10-mg group), and 1.7% (15-mg group); hypoglycemia was reported in 0.4% of those who received semaglutide. Serious adverse events were reported in 5 to 7% of the patients who received tirzepatide and in 3% of those who received semaglutide. CONCLUSIONS: In patients with type 2 diabetes, tirzepatide was noninferior and superior to semaglutide with respect to the mean change in the glycated hemoglobin level from baseline to 40 weeks. (Funded by Eli Lilly; SURPASS-2 ClinicalTrials.gov number, NCT03987919.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The text we found for this paper looks like another document, so the self-check wasn’t run.
Citations
Cites
Multiple Imputation for Nonresponse in Surveys
Rubin, D. B. (1987) · Wiley Series in Probability and Statistics · doi:10.1002/9780470316696 · Cited by 20,701
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Self-citationDavies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518
Self-citationGlucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868
Davies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., Rosenstock, J., Shimomura, I., Viljoen, A., Wadden, T. A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00213-0 · Cited by 1,419
Self-citationCoskun, T., Sloop, K. W., Loghin, C., Alsina-Fernandez, J., Urva, S., Bokvist, K. B., Cui, X., Briere, D. A., Cabrera, O., Roell, W. C., et al. (2018) · Molecular Metabolism · doi:10.1016/j.molmet.2018.09.009 · Cited by 882
Self-citationFrias, J. P., Nauck, M. A., Van, J., Kutner, M. E., Cui, X., Benson, C., Urva, S., Gimeno, R. E., Milicevic, Z., Robins, D., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32260-8 · Cited by 815
Self-citationPratley, R. E., Aroda, V. R., Lingvay, I., Lüdemann, J., Andreassen, C., Navarria, A., & Viljoen, A. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30024-x · Cited by 790
Sorli, C., Harashima, S.-I., Tsoukas, G. M., Unger, J., Karsbøl, J. D., Hansen, T., & Bain, S. C. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30013-x · Cited by 745
Ahmann, A. J., Capehorn, M., Charpentier, G., Dotta, F., Henkel, E., Lingvay, I., Holst, A. G., Annett, M. P., & Aroda, V. R. (2018) · Diabetes Care · doi:10.2337/dc17-0417 · Cited by 596
Cited by
Items 701–800 of 2,039
Breaking New Ground with Incretin Therapy in Diabetes
Tuttle, K. R. (2021) · New England Journal of Medicine · doi:10.1056/nejme2109957 · Cited by 12
Add-on value of tirzepatide versus semaglutide
Scheen, A. J. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00116-4 · Cited by 14
Ismaeil, A., Babiker, F. A., & Al‐Sabah, S. (2022) · Pharmaceuticals · doi:10.3390/ph15060720 · Cited by 15
“Recently, tirzepatide, a dual GLP-1R and GIP receptor agonist, is undergoing clinical trials for the treatment of type 2 diabetes [19].”
BackgroundGallagher, E. J., & LeRoith, D. (2022) · Cancer and Metastasis Reviews · doi:10.1007/s10555-022-10049-z · Cited by 12
“However, individuals with a history of cancer are typically excluded from clinical trials with these novel weight loss medications; therefore, it will take some time to discover whether these therapies reduce cancer risk and mortality [9].”
BackgroundLandgraf, R., Aberle, J., Birkenfeld, A. L., Gallwitz, B., Kellerer, M., Klein, H., Müller-Wieland, D., Nauck, M. A., Wiesner, T., & Siegel, E. (2022) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-1624-3449 · Cited by 12
Future Treatment Options and Regimens for Nonalcoholic Fatty Liver Disease
Francque, S., & Ratziu, V. (2023) · Clinics in Liver Disease · doi:10.1016/j.cld.2023.01.010 · Cited by 13
Tirzepatide for type 2 diabetes
Anderson, S. L., & Marrs, J. C. (2023) · Drugs in Context · doi:10.7573/dic.2023-6-1 · Cited by 21
Goldenberg, R., Teoh, H., & Verma, S. (2023) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000001084 · Cited by 11
Pharmacological Advances in Incretin-Based Polyagonism: What We Know and What We Don’t
Novikoff, A., & Müller, T. D. (2024) · Physiology · doi:10.1152/physiol.00032.2023 · Cited by 15
Till, A., Fries, C., & Fenske, W. K. (2022) · Brain Sciences · doi:10.3390/brainsci12121646 · Cited by 14
Holmager, P., Christensen, M. B., Nørgaard, K., & Schmidt, S. (2024) · Journal of Diabetes Science and Technology · doi:10.1177/19322968241289438 · Cited by 14
“…GLP-1 RA as an add-on therapy in people with T1D using an AID as they are shown to reduce postprandial glucose peaks, HbA1c, and TDD. 27 In 28-30 Two observational studies have examined the effect in people with T1D indicating an even larger effect on weight loss compared to semaglutide…”
Class B1 GPCRs: insights into multireceptor pharmacology for the treatment of metabolic disease
Sangwung, P., Ho, J. D., Siddall, T., Lin, J., Tomás, A., Jones, B. J., & Sloop, K. W. (2024) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00371.2023 · Cited by 15
Wu, J., Lin, Y., Hsu, W., Liu, T., Tsai, Y., Huang, P., Chuang, M., Yu, T., & Lai, C. (2025) · Hepatology International · doi:10.1007/s12072-025-10857-9 · Cited by 12
Babazadeh, D., Wyatt, S., & Steinberg, F. M. (2025) · Advances in Nutrition · doi:10.1016/j.advnut.2025.100491 · Cited by 16
Molecular Afterglow of Lophine‐Based Luminophore and Its Imaging Applications
Yang, J., Yang, Y.-S., Wang, H., Liang, S. H., & Ran, C. (2025) · Angewandte Chemie International Edition · doi:10.1002/anie.202507174 · Cited by 11
GLP-1 receptor agonists and next-generation metabolic hormone therapies in chronic kidney disease
Alicic, R. Z., Neumiller, J. J., & Tuttle, K. R. (2026) · Nature Reviews Nephrology · doi:10.1038/s41581-025-01036-y · Cited by 22
Design of Potent and Proteolytically Stable Biaryl-Stapled GLP-1R/GIPR Peptide Dual Agonists
Yang, Y., Lee, C., Reddy, R. R., Huang, D. J., Zhong, W., Nguyen-Tran, V. T. B., Shen, W., & Lin, Q. (2022) · ACS Chemical Biology · doi:10.1021/acschembio.2c00175 · Cited by 12
Tirzepatide for Weight Loss: Can Medical Therapy “Outweigh” Bariatric Surgery?
Novograd, J., Mullally, J. A., & Frishman, W. H. (2023) · Cardiology in Review · doi:10.1097/crd.0000000000000515 · Cited by 12
Remission of type 2 diabetes: A critical appraisal
Ricci, M., Mancebo-Sevilla, J. J., Cobos-Palacios, L., Sanz‐Cánovas, J., Sampalo, A. L., Hernández-Negrín, H., Velasco, M. Á. P., Perez-Belmonte, L. M., Bernal-López, M. R., & Gómez‐Huelgas, R. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1125961 · Cited by 14
“Today we know that the very-low-calorie diet (VLCD), a diet that contains 800 kcal per day, achieves themost significant weight loss effect in diabetic patients (25).”
BackgroundInfluentialNiu, S., Alkhuzam, K. A., Guan, D., Jiao, T., Shi, L., Fonseca, V. A., Laiteerapong, N., Ali, M. K., Schatz, D., Guo, J. S., et al. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15332 · Cited by 11
Nicholls, S. J., Tofé, S., le Roux, C. W., D’Alessio, D. A., Wiese, R. J., Pavo, I., Brown, K., Weerakkody, G. J., Zeytinoglu, M., & Romera, I. C. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02147-9 · Cited by 11
Self-citationChianelli, M., Armellini, M., Carpentieri, M. S., Coccaro, C., Cuttica, C. M., Fusco, A., Marucci, S., Nelva, A., Nizzoli, M., Ponziani, M. C., et al. (2024) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/0118715303282327240507184902 · Cited by 15
Data mining study on adverse events of tirzepatide based on FAERS database
Huo, Y., Ma, M., & Liao, X. (2024) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2024.2376686 · Cited by 14
Incretin-based therapy: a new horizon in diabetes management
Zarei, M., Vaighan, N. S., Farjoo, M. H., Talebi, S., & Zarei, M. (2024) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-024-01479-3 · Cited by 13
“However, tirazepatide dose-dependently attenuates proinsulin level, proinsulin/insulin and proinsulin/C-peptide ratios, indica - tive of ameliorated beta cell function [ 252 , 253 ].”
Central nervous system pathways targeted by amylin in the regulation of food intake
Hankir, M. K., & Foll, C. L. (2024) · Biochimie · doi:10.1016/j.biochi.2024.10.012 · Cited by 14
Shah, M. U., Roebuck, A., Srinivasan, B., Ward, J. K., Squires, P. E., Hills, C. E., & Lee, K. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1499681 · Cited by 23
The effects of GIP, GLP-1 and GLP-2 on markers of bone turnover: a review of the gut–bone axis
Longo, M., Mathiesen, D. S., Gasbjerg, L. S., Esposito, K., Lund, A., & Knop, F. K. (2025) · Journal of Endocrinology · doi:10.1530/joe-24-0231 · Cited by 14
Glucagon-like peptide-1 receptor agonists and the eye
Zhang, D. L., & Finn, A. P. (2025) · Current Opinion in Ophthalmology · doi:10.1097/icu.0000000000001137 · Cited by 15
What will the impact be of use of tirzepatide in patients with obstructive sleep apnea (OSA)?
Pack, A. I., Grunstein, R. R., Mokhlesi, B., Ryan, S., Schwab, R., & Gozal, D. (2025) · SLEEP · doi:10.1093/sleep/zsaf045 · Cited by 14
Kommu, S., Sharma, P., & Gabor, R. (2025) · Obesity Reviews · doi:10.1111/obr.13961 · Cited by 17
Brown, A., Sergent, H., Vu, A. H., Liu, H., Fisher, J. C., Somoza, E., Mei, T., Lipman, J., Park, J., Chui, P., et al. (2025) · Surgical Endoscopy · doi:10.1007/s00464-025-11942-8 · Cited by 14
“…by Frías et al. reported superior Hgba1c control with tirzepatide 5 mg,10 mg, and 15 mg compared to semaglutide 1 mg at 40 weeks (− 2.01 percentage points, − 2.24 percentage points, and − 2.30 percentage points with 5 mg, 10 mg, and 15 mg of tirzepa-tide, and − 1.86 percentage semaglutide) [32].”
InfluentialSong, Z., Tang, Y., Peng, M., Han, R., & He, P. (2025) · Pharmaceuticals · doi:10.3390/ph18091261 · Cited by 19
Allahwala, M. A., Marathe, C. S., Nelson, A. J., Psaltis, P. J., & Marathe, J. (2025) · Heart Lung and Circulation · doi:10.1016/j.hlc.2025.07.005 · Cited by 17
Insights into the Mechanism of Action of Tirzepatide: A Narrative Review
Galindo, R. J., CHENG, A. Y. Y., Longuet, C., Ai, M., Coşkun, T., Malik, R., Peleshok, J. C., Levine, J. A., & Dunn, J. P. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01804-w · Cited by 32
Huangfu, G., Jaltotage, B., Pang, J., Lan, N. S. R., Abraham, A., Otto, J. H., Ihdayhid, A. R., Rankin, J. M., Chow, B. J. W., Watts, G. F., et al. (2022) · Metabolism · doi:10.1016/j.metabol.2022.155370 · Cited by 12
Ryan, D. H., Deanfield, J. E., & Jacob, S. (2023) · Cardiovascular Endocrinology & Metabolism · doi:10.1097/xce.0000000000000279 · Cited by 12
CVOT Summit 2022 Report: new cardiovascular, kidney, and glycemic outcomes
Schnell, O., Battelino, T., Bergenstal, R. M., Birkenfeld, A. L., Ceriello, A., CHENG, A. Y. Y., Davies, M. J., Edelman, S. V., Forst, T. M., Giorgino, F., et al. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01788-6 · Cited by 13
“Recently, tirzepatide, a GIP/GLP-1 RA that significantly reduces HbA1c levels in people with T2D [75], has also been shown to have remarkable effects on body weight loss in people with and without diabetes [30].”
BackgroundSelf-citationObesity management for cardiovascular disease prevention
Hritani, R., Rifai, M. A., Mehta, A., & German, C. A. (2023) · Obesity Pillars · doi:10.1016/j.obpill.2023.100069 · Cited by 15
“There were no signi fi cant differences in LDL-C or blood pressure between the two study drugs [27].”
BackgroundYu, D., Shen, S., Zhang, J., & Wang, Q. (2023) · Clinical Therapeutics · doi:10.1016/j.clinthera.2023.06.008 · Cited by 12
Stumpf, M. A. M., Cercato, C., de Melo, M. E., Santos, R. D., & Mancini, M. C. (2023) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwad280 · Cited by 12
Al‐Zaid, B., Chacko, S., Ezeamuzie, C. I., Bünemann, M., Krasel, C., Karimian, T., Lanzerstorfer, P., & Al‐Sabah, S. (2022) · Pharmacology Research & Perspectives · doi:10.1002/prp2.1013 · Cited by 10
Albumin-binding RNAi Conjugate for Carrier Free Treatment of Arthritis
Colazo, J. M., Hoogenboezem, E. N., Keech, M. C., Francini, N., Shah, V., Yu, F., Lo, J. H., Sorets, A. G., McCune, J. T., Cho, H., et al. (2023) · doi:10.1101/2023.05.31.542971 · Cited by 11
Anker, S. D., Ji, L., Kindel, T., Coats, A. J. S., Ojji, D., Puente-Barragán, A., Rossing, P. R., Zieroth, S. R., Ahmad, S., Usman, S., et al. (2025) · Global Cardiology · doi:10.4081/cardio.2025.86 · Cited by 17
Self-citationSingh, A., Singh, A. K., Singh, R., & Misra, A. (2025) · Diabetes & Metabolic Syndrome: Clinical Research & Reviews · doi:10.1016/j.dsx.2025.103212 · Cited by 13
Weight Recidivism After Bariatric Surgery: A Narrative Review
Cao, Q., Kazi, H., Merchant, A. M., & Jawed, A. E. (2025) · The American Surgeon · doi:10.1177/00031348251337161 · Cited by 14
Feng, P., Liu, Z., Lv, D., Hao, W., Li, D., Xue, G., Bai, B., & Hölscher, C. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177972 · Cited by 11
Crisafulli, S., Alkabbani, W., Paik, J. M., Bykov, K., Tavakkoli, A., Glynn, R. J., Htoo, P. T., Yu, E. W.-Y., Trifirò, G., Wexler, D. J., et al. (2025) · Annals of Internal Medicine · doi:10.7326/annals-25-01724 · Cited by 16
Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Facts and Hopes
Adinolfi, L. E., Marrone, A., Izzi, A., & Craxì, A. (2025) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2025.103411 · Cited by 11
The evolving landscape of obesity pharmacotherapy
Petersen, J., Finan, B., Johansen, V. B. I., Müller, T. D., & Clemmensen, C. (2026) · Nature Reviews Drug Discovery · doi:10.1038/s41573-026-01427-1 · Cited by 19
“The effectiveness of tirzepatide has been characterized in multiple clinical trials evaluating its efficacy for the management of both obesity and weight-related comorbidities 41,116–120 .”
Obesity–An Update on the Basic Pathophysiology and Review of Recent Therapeutic Advances
Gjermeni, E., Kirstein, A., Kolbig, F., Kirchhof, M., Bundalian, L., Katzmann, J. L., Laufs, U., Blüher, M., Garten, A., & Duc, D. L. (2021) · Biomolecules · doi:10.3390/biom11101426 · Cited by 154
Zhang, J., Xu, H., Lu, J., Dong, Y., & Feng, J. (2023) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2023.117291 · Cited by 11
Genetically proxied impaired GIPR signaling and risk of 6 cancers
Rogers, M., Gill, D., Ahlqvist, E., Robinson, T., Mariosa, D., Johansson, M., Penha, R. C. C., Dossus, L., Gunter, M. J., Moreno, V. R., et al. (2023) · iScience · doi:10.1016/j.isci.2023.106848 · Cited by 11
“Food and Drug Administration (FDA) for type 2 diabetes treatment.(12,13) By potentiating postprandial insulin secretion and increasing blood insulin levels, there is some concern that pharmacological agonism of the GIPR signaling pathway could increase risk of hyperinsulinemia-driven cancers.”
BackgroundFrías, J. P., Galindo, R. J., Wang, H., Malik, R., Chivukula, K. K., & Maldonado, J. M. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad495 · Cited by 11
Self-citationGlucagon-based therapy for people with diabetes and obesity: What is the sweet spot?
McGlone, E. R., & Tan, T. (2024) · Peptides · doi:10.1016/j.peptides.2024.171219 · Cited by 11
Cardioprotective benefits of metabolic surgery and GLP-1 receptor agonist–based therapies
Morissette, A., & Mulvihill, E. E. (2024) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2024.07.012 · Cited by 13
NOVEL AGENTS IN THE MANAGEMENT OF DIABETES AND RISK OF WORSENING DIABETIC RETINOPATHY
Rajagopal, R., & McGill, J. B. (2024) · Retina · doi:10.1097/iae.0000000000004252 · Cited by 11
Li, J., Xie, J., Han, Y., Zhang, W., Wang, Y., & Jiang, Z. (2024) · Endocrine Journal · doi:10.1507/endocrj.ej24-0286 · Cited by 19
“Previous preclinical and clinical trials have con‐ firmed that tirzepatide provides better glycaemic control and weight loss effects than semaglutide does [9, 10].”
Moreira, R. O., Valério, C. M., Hohl, A., Moulin, C., Moura, F., Trujilho, F. R., Gerchman, F., Corrêa, L. L., Mancini, M. C., de Melo, M. E., et al. (2024) · Archives of Endocrinology and Metabolism · doi:10.20945/2359-4292-2024-0422 · Cited by 29
Kamrul-Hasan, A. B. M., Patra, S., Dutta, D., Nagendra, L., Muntahi-Reza, A., Borozan, S., & Pappachan, J. M. (2025) · World Journal of Diabetes · doi:10.4239/wjd.v16.i2.101282 · Cited by 17
Glucagon-like peptide-1 receptor agonists to improve cardiorenal outcomes: data from FLOW and beyond
Faruque, L. I., Yau, K., & Cherney, D. Z. I. (2025) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000001066 · Cited by 12
Osumili, B., Sapin, H., Yang, Z., Ranta, K., Paik, J. S., & Blüher, M. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01728-5 · Cited by 16
Chen, J.-J., Hsu, C., Hung, C., Liang, C., Su, K., Carvalho, A. F., Stubbs, B., Chen, Y.-W., Chen, T., Lei, W., et al. (2025) · Pharmaceuticals · doi:10.3390/ph18050735 · Cited by 14
A Contemporary Rationale for Agonism of the GIP Receptor in the Treatment of Obesity
Samms, R. J., & Sloop, K. W. (2025) · Diabetes · doi:10.2337/dbi24-0026 · Cited by 27
Stensen, S., Krogh, L. S. L., Sparre‐Ulrich, A. H., Dela, F., Hartmann, B., Vilsbøll, T., Holst, J. J., ROSENKILDE, M. M., Christensen, M., Gasbjerg, L. S., et al. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14736 · Cited by 11
“Blood samples for analysis of plasma/serum glucose, glucagon, total GIP, total GLP-1, GIP(3-30)NH2, C-peptide, insulin, paracetamol, and lipids, as well as the SAT biopsies, were handled as previously described.”
BackgroundMethodInfluentialNovel Approaches to the Management of Diabetes Mellitus in Patients with Coronary Artery Disease
Oikonomou, E. K., Xenou, M., Zakynthinos, G. Ε., Tsaplaris, P., Lampsas, S., Bletsa, E., Gialamas, I., Kalogeras, K. I., Goliopoulou, A., Gounaridi, M. I., et al. (2023) · Current Pharmaceutical Design · doi:10.2174/1381612829666230703161058 · Cited by 12
Beta‐cell function in type 2 diabetes ( T2DM ): Can it be preserved or enhanced?
Kassem, L. S., Rajpal, A., Barreiro, M. V. E., & Ismail‐Beigi, F. (2023) · Journal of Diabetes · doi:10.1111/1753-0407.13446 · Cited by 16
“185 Further research is needed to understand the basic mechanisms underlying the reversal of the otherwise progressive loss of beta-cell function in patients with T2DM.”
BackgroundGupta, S., & Chen, M. (2023) · Clinical Medicine · doi:10.7861/clinmed.2023-0183 · Cited by 19
Ruocco, C., Malavazos, A. E., Ragni, M., Carruba, M. O., Valerio, A., Iacobellis, G., & Nisoli, E. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106892 · Cited by 10
Advances in obesity pharmacotherapy; learning from metabolic surgery and beyond
Tsilingiris, D., & Kokkinos, A. D. (2023) · Metabolism · doi:10.1016/j.metabol.2023.155741 · Cited by 16
Incretin Therapies for Patients with Type 2 Diabetes and Chronic Kidney Disease
Alicic, R. Z., & Neumiller, J. J. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm13010201 · Cited by 16
“Additionally, evidence continues to mount suggesting similar organ protective effects with the dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) agonist, tirzepatide [30,31].”
BackgroundLe, T. T. B., Minh, L. H. N., Devi, P., Islam, N., & Sachmechi, I. (2024) · Cureus · doi:10.7759/cureus.51460 · Cited by 20
“Compared to the GLP-1 receptor agonist, tirzepatide is a novel, subcutaneous, once-weekly dual GIP/GLP-1 RA drug that has been demonstrated to be superior in controlling HbA1c levels and reducing body weight [10].”
BackgroundMainieri, F., Bella, S. L., Rinaldi, M., & Chiarelli, F. (2024) · European Journal of Pediatrics · doi:10.1007/s00431-024-05427-4 · Cited by 15
Targeting obesity for therapeutic intervention in heart failure patients
Sato, R., & von Haehling, S. (2024) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2024.2363395 · Cited by 10
Current treatment landscape for obesity in Singapore
Lee, P. C., Lim, C. H., Asokkumar, R., & Chua, M. W. J. (2023) · Singapore Medical Journal · doi:10.4103/singaporemedj.smj-2022-216 · Cited by 15
Hsu, C., Hsuan, C., Liao, D., Chang, J. K.-J., Chang, A. J.-W., Hee, S., Lee, H.-L., & Teng, S. I. F. (2023) · Life · doi:10.3390/life13041024 · Cited by 14
SNAITH, J. R., Narongkiatikhun, P., Bjornstad, P., Greenfield, J. R., & Tommerdahl, K. L. (2025) · Diabetes Care · doi:10.2337/dci25-0015 · Cited by 19
Chen, N., Zhang, M., Shi, B., Luo, X., Huang, R., Luo, Z., He, J., Xue, S., Li, N., Ling, Z., et al. (2025) · Journal of Orthopaedic Translation · doi:10.1016/j.jot.2025.09.002 · Cited by 12
“…of TZP versus semaglutide, which is currently the strongest glucose-lowering GLP-1R agonist, and the results showed that the HbA1c was decreased by 0.15 % (P = 0.02), 0.39 % (P 0.001) and 0.45 % (P 0.001) in TZP 5 mg, 10 mg and 15 mg groups versus semaglutide 1 mg group, respectively[25].”
InfluentialGhaleb, J., Khouzami, K. K., Nassif, N., Attieh, P., Ajlani, M. F. A., Sleiman, J. B., Khalouf, A., Harb, F., Azar, S. T., Kanaan, A., et al. (2025) · International Journal of Endocrinology · doi:10.1155/ije/2876156 · Cited by 11
“Moreover, tirzepatide therapy produced an increase in HDL cholesterol and lipoprotein lipase levels when compared to selective GLP-1 agonist treatment alone [20, 21].”
Oestrogen changes at menopause: insights into obesity-associated breast risk and outcomes
Sho, M., Qureshi, R., & Slingerland, J. M. (2025) · Nature Reviews Endocrinology · doi:10.1038/s41574-025-01208-7 · Cited by 10
“Glucagon-like peptide 1 receptor agonists (GLP1RAs) and the newer dual agonist for GLP1 and gastric inhibitory polypeptide (GIP; also known as glucose-dependent insulinotropic polypeptide) receptors, tirzepatide, are approved for type 2 diabetes mellitus and obesity 140–143 .”
Glucagon-like peptide-1 medicines and cancer
Yabut, J. M., & Drucker, D. J. (2026) · Nature Cancer · doi:10.1038/s43018-025-01110-1 · Cited by 15
GLP-1 receptor agonist use and cancer risk in obese nondiabetic adults
Hsu, A. H.-C., Ramirez, P. T., Chang, Y.-H., Chiang, Y. C., Santía, M. C., Meschini, T., Mateo-Kubach, P., Suri, A., & Kamat, A. A. (2026) · Annals of Oncology · doi:10.1016/j.annonc.2026.04.013 · Cited by 12
Ceriello, A., Rodbard, H. W., Battelino, T., Brosius, F. C., Cosentino, F., Green, J., Ji, L., Kellerer, M., Koob, S., Kosiborod, M., et al. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01993-3 · Cited by 12
Mody, R., Valentine, W. J., Hoog, M. M., Sharland, H., & Belger, M. A. (2024) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2024.30.2.153 · Cited by 13
Current Status of Therapeutic Peptides for the Management of Diabetes Mellitus
Prajapati, A., Rana, D., Rangra, S., Jindal, A. B., & Benival, D. M. (2024) · International Journal of Peptide Research and Therapeutics · doi:10.1007/s10989-024-10590-1 · Cited by 10
Urva, S., Levine, J. A., Schneck, K. B., & Tang, C. C. (2024) · Current Medical Research and Opinion · doi:10.1080/03007995.2024.2322072 · Cited by 12
Singh, A., & Nissen, S. E. (2024) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2024.0122 · Cited by 11
“30 Another study found that the addition of tirzepatide to insulin glargine resulted in improved glycemic control, weight loss, and less hypoglycemia, highlighting incretin-modulating therapies as potentially paradigm changing for patients with T2DM requiring insulin.”
Huang, X., Wu, M., Lin, J., Mou, L., Zhang, Y., & Jiang, J. (2024) · Medicine · doi:10.1097/md.0000000000038236 · Cited by 11
Larsen, A. T., Mohamed, K. E., Melander, S. A., Karsdal, M. A., & Henriksen, K. (2024) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00092.2024 · Cited by 12
Hirsch, I. B., Parkin, C. G., Cavaiola, T. S., & Bergenstal, R. M. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15883 · Cited by 8
Wen, J., Nadora, D., Bernstein, E., How-Volkman, C., Truong, A., Akhtar, M., Prakash, N. A., Puglisi, J. L., & Frezza, E. E. (2024) · Cureus · doi:10.7759/cureus.69008 · Cited by 21
“Across all nine studies, there were a total of 5,445 patients, with a total of 5,183 patients who completed the studies [6-14].”
BackgroundInfluentialFitch, K. V., Zanni, M. V., Manne‐Goehler, J., Diggs, M. R., Gattu, A. K., Currier, J. S., Bloomfield, G. S., Hsiao, C.-B., Gupta, S. K., Aberg, J. A., et al. (2024) · Annals of Internal Medicine · doi:10.7326/annals-24-00944 · Cited by 10
Does Incretin Agonism Have Sustainable Efficacy?
Janket, S., Chatanaka, M. K., Sohaei, D., Tamimi, F., Meurman, J. H., & Diamandis, E. P. (2024) · Cells · doi:10.3390/cells13221842 · Cited by 11
Novel neural pathways targeted by GLP-1R agonists and bariatric surgery
Hankir, M. K., & Lutz, T. A. (2024) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-024-03047-3 · Cited by 16
“…the clinic or are still under clinical development and promise to be even more effective than semaglu-tide, such as the dual GLP-1R and glucose-dependent insu-linotropic peptide receptor (GIPR) agonist tirzepatide [4] and the triple GLP-1R, GIPR, and glucagon receptor (GR) agonist retatrutide [5].”
Smart control lipid-based nanocarriers for fine-tuning gut hormone secretion
Xu, Y., Michalowski, C. B., Koehler, J. A., Darwish, T., Guccio, N., Alcaino, C., Domingues, I., Zhang, W., Marotti, V., Hul, M. V., et al. (2024) · Science Advances · doi:10.1126/sciadv.adq9909 · Cited by 10
“The value of such approaches has been demonstrated by positive outcomes in clinical trials of GLP1-based dual and triple agonist therapies ( 12 , 53 , 54 ).”
Characteristics and Dosing Patterns of Tirzepatide Users with Type 2 Diabetes in the United States
Mody, R., Desai, K. R., Teng, C., Reznor, G., Stockbower, G. E., Grabner, M., & Benneyworth, B. D. (2025) · Diabetes Therapy · doi:10.1007/s13300-024-01684-6 · Cited by 15
“…statistically significant and clinically meaningful reductions in HbA1c and body weight versus placebo (SUR‑ PASS‑1, SURPASS‑5) [12, 13], and active compar‑ ators including semaglutide 1 mg (SURPASS‑2) [14], titrated insulin degludec (SURPASS‑3) [15], and titrated insulin glargine (SURPASS‑4) [16].”
Cazac, G.-D., Lăcătușu, C.-M., Grigorescu, E.-D., Foșălău, A.-B., Onofriescu, A., & Mihai, B. M. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14041042 · Cited by 10
Emerging role of GLP-1 agonists in cardio-metabolic therapy - Focus on Semaglutide
Odigwe, C. I., Mulyala, R. R., Malik, H., Ruiz, B., Riad, M., Sayiadeh, M. A., Honganur, S., Parks, A., Rahman, M. U., & Lakkis, N. M. (2025) · American Heart Journal Plus Cardiology Research and Practice · doi:10.1016/j.ahjo.2025.100518 · Cited by 17
“…looking into medications with dual biologic pathways like Tirzepatide, which have co-agonist action on (GLP1 and GIP glucagon insulinotropic polypeptide) receptors have been shown to be more effective in diabetic, weight loss and lipid control (SURPASS-2 Trial) [68], the effect on weight loss.”
Availability of Cardioprotective Medications for Type 2 Diabetes in the Medicaid Program
Makam, A. N., Bailey, L. R. J., Anderson, N., Bellitti, K., Skinner, S., & Nguyen, O. K. (2025) · Annals of Internal Medicine · doi:10.7326/annals-24-01449 · Cited by 10
Huang, Y., Chen, J.-C., Li, P., Hsu, M., Cheng, C., Meyerowitz‐Katz, G., & Su, P. (2025) · Communications Medicine · doi:10.1038/s43856-025-01066-4 · Cited by 11
“Throughout the SURPASS program, Tirzepatide ’ s overall ocular-adverse-event pro fi le was comparable to comparators, and adjudicated analyses detected no signal for early diabetic-retinopathy worsening 37 .”
Innovative Molecules and Delivery Technologies Enabling the Future of GLP-1-based Therapies
Xu, Y., Drucker, D. J., Traverso, G., & Beloqui, A. (2025) · Endocrine Reviews · doi:10.1210/endrev/bnaf027 · Cited by 12
Metadata
- Authors
- Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., & Brown, K.
- Affiliations
- University of Leicester (GB)
- From the National Research Institute, Los Angeles (J.P.F.); the Diabetes Research Centre, University of Leicester, and the National Institute of Health Research Leicester Biomedical Research Centre — both in Leicester, United Kingdom (M.J.D.); the Dallas Diabetes Research Center at Medical City, Dallas (J.R.); Centro de Investigaciones Metabólicas, Buenos Aires (F.C.P.M.); and Eli Lilly, Indianapolis (L.F.L., B.K.B., B.L., X.C., K.B.).
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-08-05
- Volume
- 385
- Issue
- 6
- Pages
- 503-515
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3177122952
- Cited by
- 2,096
- References
- 25
- Citations by year
- 2026: 526 · 2025: 556 · 2024: 396 · 2023: 351 · 2022: 208 · 2021: 57
- FWCI
- 188.92
- Type
- journal article
- Language
- en
- Open access
- green
- figshare.com
- Licence
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Figshare (submittedVersion, cc-by)
- Funders
- Eli Lilly and Company
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- semaglutide, type 2 diabetes, HbA1c, GLP-1 receptor agonists, GIP/GLP-1 dual agonist, non-inferiority, weight loss, gastrointestinal adverse effects, drug safety, dose comparison, glycemic control, adverse drug reactions, hypoglycemia
- MeSH terms
- Glucagon-Like Peptide-1 Receptor Agonists, Tirzepatide, Semaglutide, Blood Glucose, Diabetes Mellitus, Type 2, Dose-Response Relationship, Drug, Drug Administration Schedule, Drug Therapy, Combination, Glucagon-Like Peptides, Female, Gastric Inhibitory Polypeptide, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Injections, Subcutaneous, Male, Metformin, Middle Aged, Nausea, Weight Loss, Incretins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.